Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients

Table 3

Predictors of VTE events during the first 3 months and 12 months following CVP catheter placement, identified by univariate and multivariate regression analysis.

	Univariate analysis or (95% CI) 𝑃 value	Multivariate analysis or (95% CI) 𝑃 value
3 Months catheter-related VTE event
Lung cancer	5.3 (1.98 to 14.1) 𝑃=0.0001	5.45 (1.87 to 15.87) 𝑃=0.002
Khorana score ≥ 3	2.65 (0.88 to 8.0) 𝑃=0.08	3.50 (1.00 to 12.30) 𝑃=0.05
Low performance status	4.82 (1.08 to 21.4) 𝑃=0.03	4.68 (0.97 to 22.4) 𝑃=0.054
Metastatic stage	2.33 (0.86 to 6.37) 𝑃=0.09	1.21 (0.41 to 3.61) 𝑃=0.73
Previous VTE event	1.76 (0.54 to 5.86) 𝑃=0.34
Age > 70	0.69 (0.24 to 2.00) 𝑃=0.50
Platinum based chemotherapy	1.72 (0.66 to 4.45) 𝑃=0.26
Chemotherapy within 0 to 8 days after CVP placement	1.00 (0.62 to 1.57) 𝑃=0.98
3 months VTE event at any location
Khorana score ≥ 3	2.59 (0.99 to 6.77) 𝑃=0.05	3.56 (1.26 to 10.74) 𝑃=0.01
Lung cancer	3.07 (1.37 to 6.87) 𝑃=0.006	2.56 (1.06 to 6.17) 𝑃=0.03
CVP inserted left	3.04 (0.89 to 10.3) 𝑃=0.07	2.39 (0.64 to 8.89) 𝑃=0.19
Platinum based chemotherapy	2.01 (0.90 to 4.5) 𝑃=0.09	1.84 (0.74 to 4.54) 𝑃=0.18
Respiratory failure	2.47 (1.11 to 5.49) 𝑃=0.02
Metastatic stage	1.96 (0.86 to 4.46) 𝑃=0.11
Low performance status	1.64 (0.67 to 4.04) 𝑃=0.28
Previous VTE event	1.42 (0.50 to 4.06) 𝑃=0.50
12 months VTE event at any location
Khorana score ≥ 3	2.66 (1.50 to 4.70) 𝑃=0.001	2.67 (1.49 to 4.78) 𝑃=0.001
Lung cancer	2.16 (1.34 to 3.49) 𝑃=0.002	1.93 (1.15 to 3.25) 𝑃=0.01
Bevacizumab based chemotherapy	2.51 (0.89 to 7.11) 𝑃=0.08	3.04 (0.98 to 9.44) 𝑃=0.054
Platinum based chemotherapy	1.49 (0.93 to 2.37) 𝑃=0.09	1.51 (0.89 to 3.25) 𝑃=0.12
Respiratory failure	1.75 (1.09 to 2.82) 𝑃=0.02
Metastatic stage	1.49 (0.93 to 2.37) 𝑃=0.17
Low performance status	2.24 (1.33 to 3.78) 𝑃=0.002
Previous VTE event	1.35 (0.71 to 2.56) 𝑃=0.35
CVP inserted left	2.20 (1.13 to 4.26) 𝑃=0.02